Navigation Links
Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
Date:10/25/2011

AMSTERDAM, October 25, 2011 /PRNewswire/ --

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today provided an update on operations and disclosed the outcome of a strategic review of its gene therapy product pipeline conducted by management and AMT's Board of Directors that enables the company to remain at the forefront of gene therapy development. The CHMP's recent opinion, while not approving Glybera®, did not identify any safety risks with AMT's adeno-associated virus vector technology. This will allow AMT to leverage its expertise and strength in building other portfolio products. The selection of specific pipeline products is aimed at securing partnering agreements that will provide solid financial foundations to take the company forward. Existing shareholders continue to see promise in the technology and are in discussions with AMT to provide additional equity.

Pipeline

AMT will focus development efforts and financial resources on three gene therapy programs: hemophilia B, GDNF and acute intermittent porphyria. The Company will continue participating in the SanfilippoB program, which is fully funded by a consortium led by Institut Pasteur. Further investment in and development of Glybera and the Duchenne's muscular dystrophy program has been suspended.

The company intends to support the development of its product pipeline through partnering agreements. Negotiations are being conducted for two programs.

Glybera®

Following the negative opinion provided by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for Glybera (alipogene tiparvovec) as a treatment of lipoprotein lipase deficiency (LPLD), AMT has suspended the program. Consequently, AMT does not expect that Glybera will reach European patients. AMT decided that further investment in Glybera, in light of requirements necessary for approval and with the current financi
'/>"/>

SOURCE Amsterdam Molecular Therapeutics (AMT) B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Receives Opinion on Re-examination of Glybera® Marketing Authorisation Application
2. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
3. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
4. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
5. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
6. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
7. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
8. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
9. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
11. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... -- Neogen Corporation (NASDAQ: NEOG ) announced today that ... with Illumina (NASDAQ: ILMN ), the global leader ... market and sell arrays with Neogen,s custom SNP content, ... the global agrigenomics community. Neogen is one ... genomics laboratory in Lincoln, Neb. ...
(Date:7/7/2015)... ... 07, 2015 , ... The global aptamers market is expected ... a CAGR of 17.89% between 2015 and 2020. The aptamer type segments included ... applications, the report is segmented into diagnostics, therapeutics development, R&D, and other applications. ...
(Date:7/7/2015)... ... July 07, 2015 , ... The Pistoia Alliance, a global, ... life science R&D, has attracted a number of new members from across the ... company joining as a Core member, and DNAnexus and Tessella as Participating members. ...
(Date:7/6/2015)... July 6, 2015  Approximately 1% of the population ... their chromosomes. These individuals are three times more likely ... in one of the nation,s leading medical journals by ... Canada.  Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... (HHV-6) causes roseola (also known as "sixth disease") and ...
Breaking Biology Technology:Neogen signs commercialization agreement with Illumina 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 2Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 3Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 4Aptamers Market Growing at 17.89% CAGR to 2020 – New Research Available at RnRMarketResearch.com 5Pistoia Alliance Continues to Attract New Members 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... China, May 11, 2010 /PRNewswire-Asia/ --, -- Revenue increased 26.4% to ... margins increased more, than 200 basis points to ... Year Over Year, -- Sales of PurCotton(R) products increased 71.1% to ... to $0.32 from $0.15 of, the first six ...
... China , May 11 /PRNewswire-Asia-FirstCall/ -- China,Baicaotang Medicine Ltd. ... distribution and retailing in the, Guangxi Province of China ... research coverage on the,Company. , , ... Mr. Tang Hui Tian , Chairman and ...
... SHENYANG, China , May 11 /PRNewswire-Asia-FirstCall/ -- ... China -based biotechnology,company focused on researching, developing, manufacturing and marketing,biopharmaceutical products, today ... March 31, 2010 on May 16, 2010 ,at ... , ...
Cached Biology Technology:Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 2Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 3Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 4Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 5Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 6Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 7Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 8Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 9Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 10Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 11Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 12Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 13Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 14Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 15Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 16Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 17Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 18Winner Medical Reports Second Quarter Results for the Fiscal Year 2010 19Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 2Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd. 33SBio Inc. To Report 2010 First Quarter Unaudited Financial Results on May 16, 2010 2
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ) ... Biometrics Market by Application, Technology, Function & Geography - ... The next generation biometrics market is expected ... of 17.9% between 2015 and 2020 Travel ... Safran SA ( France ), ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... 25, 2015 According to ... (Swipe & Area), Technology, Material (Optical Prism, Piezoelectric, ... Security & Others) & Geography - Global Forecast ... said market is expected to reach $14,500.07 Million ... Browse 76 market Tables and 109 ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4
... climate change will affect interactions between species in research published ... . This knowledge, they say, is critical to making accurate ... be impacted by rising temperatures. "There is ... how species interact with one another, and that this is ...
... a long time that some creatures evolve more quickly than ... it may be that height plays a role, says Robert ... Evolutionary Synthesis Center. In a study to be ... Lanfear and colleagues report that shorter plants have faster-changing genomes. ...
... When infections occur in the body, stem cells in ... differentiating into mature immune cells that can fight off ... cell populations, potentially leading to the development of serious ... researchers led by biologists at the California Institute of ...
Cached Biology News:UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Small but speedy: Short plants live in the evolutionary fast lane 2Keeping stem cells strong 2
... Facilitates the simple, phenol-free extraction of genomic ... requiring proteinase K digestion.Each kit is designed ... preparations of up to 25 mg of ... Purification and Amplification of Genomic DNA, Nucleon ...
... 50. For rapid and efficient purification of ... than 15 minutes by gravity flow.Prepacked with ... containing 0.15% Kathon CG/ICP Biocide.Available in three ... (NAP-5), 1 ml (NAP-10) or 2.5 ...
Human ROR1 Affinity Purified Polyclonal Ab...
Human Rad1 MAb (Clone 33)...
Biology Products: